Welcome to the 43rd Annual Diabetes Symposium
Date: Thursday, April 2, 2020
Time: 7:40 a.m. to 4:45 p.m.
Up to 7.5 CME credits. Breakfast and lunch will be provided.
Who should attend?
Practicing physicians, house officers, physician assistants, nurse practitioners, and other medical personnel who treat or educate patients with diabetes.
For any questions, please contact:
Lynne J. Brecker, RN, BSN, Certified Diabetes Educator at MedStar Union Memorial Hospital
[email protected] | 410-554-4527
Location:
MedStar Union Memorial Hospital | Conference Center
201 E. University Parkway, Baltimore, MD 21218
Free parking is available at the Homewood garage, 2614 N Charles Street.
Shuttle service is available.
Cost:
$150.00 for practicing physicians
$75.00 for house officers, physicians assistants, nurse practitioners and other medical personnel.
Registration:
Reserve your spot by calling 866-493-1977 to register or register online.
Registration deadline: March 26, 2020
Course participants desiring overnight accommodations should contact the Diabetes and Endocrine Center at MedStar Union Memorial Hospital at 410-554-4527 for suggestions.
Learn more about Diabetes and Endocrinology at MedStar Union Memorial.
Program Schedule
Issam Cheikh, MD, FACP, FACE – Presiding
7:40 a.m. Registration and Continental Breakfast
8 a.m. Welcome and Introductory Remarks
Dana H. Frank, MD
8:05 a.m. Updates on Diabetes—43 years
Issam E. Cheikh, MD
8:40 a.m. Diabetes Diagnosis and Treatment in the Age of Precision Medicine
Alan Shuldiner, MD
9:30 a.m. Etiology of Type 2 Diabetes
Ralph A. DeFronzo, MD
10:20 a.m. Coffee Break
10:40 a.m. Beyond Hemoglobin A1c: Better Measures of Diabetes Control
Pamela R. Schroeder, MD, PhD
11:20 a.m. Eye Disease in Diabetes
Maria S. Romero, MD
Mansur Shomali, MD – Presiding
12:05 p.m. Lunch Break
1:05 p.m. Improving Cardiac and Renal Outcomes Utilizing SGLT2 Inhibitor
Sevil Aliyeva, MD
1:45 p.m. Nonglycemic Effects of GLP1 Agonists
Rani S. Kulkarni, MD
2:25 p.m. Diabetes and Bone Health
Malek E. Cheikh, MD
3:05 p.m. Beyond Basal Insulin—What to Add Next
Paul A. Sack, MD
3:45 p.m. How Data and Technology are Transforming Diabetes Care
Mansur E. Shomali, MD
4:30 p.m. Summary and Closing Remarks
Issam E. Cheikh, MD
4:45 p.m. Adjourn
Meet the Speakers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sevil Aliyeve, MD
Issam E. Cheikh, MD, FACP, FACE
Malek E. Cheikh, MD
Ralph A. DeFronzo, MD
Dana H. Frank, MD, FACP
Rani S. Kulkarni, MD
Maria Romero, MD
Paul A. Sack, MD, FACE
Pamela R. Schroeder, MD, PhD, FACE
Mansur E. Shomali, MD, C.M.
Alan R. Shuldiner, MDPlanning Committee
The topics for Update on Diabetes XLIII were selected to update the attendees on the latest scientific data and clinical applications for the research of diabetes. The program was assembled by Dr. Issam E. Cheikh and the Endocrinology faculty at MedStar Union Memorial Hospital.
Course Goals and Objectives
Target Audience
This program is designed to be a multidisciplinary program and is intended for a wide range of medical practitioners who are interested in the latest information on the treatment of diabetes. The program is targeted for hospital-based physicians, community physicians, fellows, residents, medical students, nurse practitioners, physician assistants, nurses, pharmacists, dietitians/nutritionists, and other members of the healthcare team who have an interest in the treatment of diabetes.
Learning Objectives
Upon completion of this program, participants will be able to:
- Appreciate the improvement of diabetes care over the past half century.
- Discuss both opportunities and challenges of precision medicine and how this new paradigm may lead to better individualized treatment of Type 2 diabetes.
- Review the pathophysiology of Type 2 diabetes with an emphasis on optimal treatment.
- Identify blood glucose metrics such as average glucose and time in range to select and adjust therapies on an individual basis.
- Describe various ophthalmic conditions likely to be encountered in patients with diabetes, with a focus on diabetic retinopathy, screening methods, and interpretation of reports.
- Review the evidence supporting the cardiovascular safety of SGLT2 inhibitors to better assess strategies that can reduce risk of cardiovascular and kidney disease in patients with Type 2 diabetes.
- Identify how to use GLP-1 agonist therapies for patients with Type 2 diabetes at increased risk for cardiovascular disease to achieve guideline recommended targets for glycemic, lipid, and blood pressure control.
- Explain the link between diabetes and bone disease and the effect of diabetes therapy on bone strength.
- Recognize the risks and benefits of adding meal time insulin versus non-insulin therapies for patients with uncontrolled Type 2 diabetes on basal insulin alone.
- Express how members of the health care team can integrate data and evidence-based technology tools in clinical practice to improve diabetes care.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by MedStar Health. MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 7.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
MedStar Union Memorial Hospital reserves the right to cancel any educational program due to unforeseen circumstances.
The topics for Update on Diabetes XLIII were chosen to give an overview of advances in diabetes care. The faculty of this program has been selected from national and local experts for their ability to present complicated and new information clearly and authoritatively. After this activity, the knowledge gained from attending this symposium will enable attendees to improve the care of patients with diabetes.
